BSE filing, BSE: 544248. Summary written from the filing by ALFA Finder's alert engine.
Mach Travel Solutions Ltd: key numbers
- Share price
- ₹220.35
- Market cap
- ₹463.6 Cr
- Revenue (annual)
- ₹230.4 Cr
- Net profit (annual)
- ₹15.66 Cr
- P/E (TTM)
- 29.6×Sector 34.9×
- Promoter holding
- 74.83%
- FII holding
- 3.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mach Travel Solutions Ltd
All →Mach Travel Solutions Earnings Call Transcript: Key Takeaways
Revenue surged 175% YoY to ₹204.5 Cr, but PAT margin nearly halved to 4.5% as management front-loaded headcount. Tone is upbeat, while hard numbers on forward guidance are largely withheld.
- Call
- Guides 25% growth
Mach Travel Solutions Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹204.53 Cr (+174.7% YoY) and PAT ₹9.26 Cr (+47.0%). H1 revenue ₹348.86 Cr already exceeds FY26 total. EBITDA margin compressed to 7.00%. Strategy: integrated MICE-plus-travel platform.
- Call
- Guides 150% growth
Mach Travel Solutions Results Update
Mach Travel Solutions Limited reported its highest-ever H1 revenue of ₹348.86 Crore for FY27. Quarterly PAT rose 46.9% YoY to ₹9.26 Crore alongside upwardly revised annual revenue guidance.
- Value
- ₹348.9 Cr
Mach Travel Solutions Q2 FY27 Results: Net Profit ₹9.3 Cr, Up 47.6% YoY
Mach Travel Solutions Ltd reported revenue from operations of ₹204.5 Cr (+174.5% YoY) and net profit of ₹9.3 Cr (+47.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹9.3 Cr · +47.6% YoY
Mach Travel Solutions Board Meeting Date
Mach Travel Solutions intimated BSE of a board meeting scheduled for November 3, 2026 to consider un-audited Q1/H1 FY27 results. No decisions have been made yet; agenda items are proposed only.
Mach Travel Solutions Business Update
Mach Travel Solutions was empanelled by MPSTDC under the 10,000-pilgrim Tirth Yatra Scheme. No specific contract value or work order is disclosed for this empanelment.
Other product launch announcements
All →AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
Raama Finance Product Launch
Raama Finance launched 'Rupya Lelo', a digital lending platform offering instant personal loans, on October 6, 2026. The product is available only in India, and no loan amount or financial figure is disclosed.
Puravankara Product Launch
Puravankara will launch the residential project Purva Cityspire Phases 1, 2 and 3 in Ernakulam on 15 November 2026. The project is RERA-registered and is being developed by two wholly owned subsidiaries.
JBM Auto Product Launch
JBM Electric Vehicles launched the all-electric ECOLIFE e12 city bus at Singapore Urban Mobility Week 2026. It cites 20,000-bus annual capacity and a new Singapore APAC hub.
- electric bus manufacturing capacity
- 20000.0 buses per annum
Restaurant Brands Asia Product Launch
Burger King India launches a limited-edition Avengers: Doomsday Collection across nationwide restaurants. The menu features themed burgers, sides, and merchandise starting at ₹199.
Hero MotoCorp Product Launch
Hero MotoCorp unveiled new motorcycles at EICMA 2026 and started VIDA customer deliveries across Europe. The company also introduced Novus Labs, its future-mobility innovation hub.